О.А. Pavlikova1,2, D.V. Pasynkov1,2,4, L.Kh. Mukhamatgaleeva1,2, O.O. Pasynkova2, I.V. Klyushkin3, A.L. Fedorov2
1Oncology Dispensary of Mari El Republic, Yoshkar-Ola
2Mari State University, Yoshkar-Ola
3Kazan State Medical University, Kazan
4Kazan State Medical Academy ― Branch Campus of the FSBEI FPE RMACPE MOH Russia, Kazan
Pavlikova Оlga А. — Cand. of Sci. (Med.), oncologist of the department of antitumor drug therapy of the Oncology Dispensary of Mari El Republic
22 Osipenko St., Yoshkar-Ola, 424000, Russian Federation, tel. +7-926-729-43-15, e-mail: email@example.com, SPIN-код: 6591-5244, ORCID ID: 0000-0003-3089-8256
Purpose. Breast cancer (BC) is the most prevalent malignancy in women. Nowadays we have a rich armamentarium of anti-cancer medications indicated for this pathology, however in the clinical settings the drug resistance is frequently seen. In such cases of hormone-sensitive HER2-negative (HER2-) BC the inhibitors of cyclin-dependent kinases may be used. Ribociclib is the representative of this family.
Material and methods. We present a case of ribociclib therapy of the metastatic hormone-sensitive HER2- BC, refractory to the previous endocrine therapy.
Results. In the described case the ribociclib therapy associated with the partial response of 16+ months duration as well as the quality of life improvement.
Conclusion. Ribociclib represents the convenient and well-tolerated therapy which is able to preserve and even improve the quality of life in patients with metastatic hormone-sensitive HER2- BC, as presented in the article.
Key words: breast cancer, CDK4/6 inhibitors, ribociclib, durable partial response.